PE Anti-Granzyme B antibody [EPR8260],Abcam,AB303034

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

IHC-P, Flow Cyt (Intra), Flow Cyt, Target Binding Affinity, Antibody Labelling

Conjugate

PE

Platform ID

BAB050352584

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NamePE Anti-Granzyme B antibody [EPR8260]
Cat. No.AB303034
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationPE
ApplicationIHC-P, Flow Cyt (Intra), Flow Cyt, Target Binding Affinity, Antibody Labelling
ClonalityMonoclonal
Clone NumberEPR8260
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Abundant protease in the cytosolic granules of cytotoxic T-cells and NK-cells which activates caspase-independent pyroptosis when delivered into the target cell through the immunological synapse (PubMed : 1985927, PubMed : 3262682, PubMed : 3263427). It cleaves after Asp (PubMed : 1985927, PubMed : 8258716). Once delivered into the target cell, acts by catalyzing cleavage of gasdermin-E (GSDME), releasing the pore-forming moiety of GSDME, thereby triggering pyroptosis and target cell death (PubMed : 31953257, PubMed : 32188940). Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -9 and -10 (CASP3, CASP9 and CASP10, respectively) to give rise to active enzymes mediating apoptosis (PubMed : 9852092). Cleaves and activates CASP7 in response to bacterial infection, promoting plasma membrane repair (By similarity). See full target information GZMB

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.